Gastrointestinal stromal tumor: a clinical overview.

PubWeight™: 1.01‹?› | Rank: Top 15%

🔗 View Article (PMID 19248971)

Published in Hematol Oncol Clin North Am on February 01, 2009

Authors

Richard Quek1, Suzanne George

Author Affiliations

1: Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

Articles by these authors

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (2006) 12.98

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet (2007) 6.76

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med (2006) 4.52

Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol (2006) 2.66

Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res (2009) 1.99

Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res (2007) 1.94

Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res (2010) 1.89

Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.82

A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst (2008) 1.63

Locoregional recurrence after preoperative radiation therapy for retroperitoneal sarcoma: adverse impact of multifocal disease and potential implications of dose escalation. Ann Surg Oncol (2013) 1.63

Adolescent and young adult oncology. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2012) 1.55

Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol (2011) 1.54

Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med (2003) 1.51

Small molecule tyrosine kinase inhibitor and depression. J Clin Oncol (2008) 1.51

Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Cancer (2014) 1.43

Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer (2013) 1.32

Soft tissue sarcoma, version 2.2014. J Natl Compr Canc Netw (2014) 1.15

Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma. Int J Radiat Oncol Biol Phys (2010) 1.14

CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin Cancer Res (2008) 1.11

A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol (2013) 1.10

Leiomyosarcoma of the inferior vena cava: survival after aggressive management. Ann Surg Oncol (2007) 1.10

Predictors for major wound complications following preoperative radiotherapy and surgery for soft-tissue sarcoma of the extremities and trunk: importance of tumor proximity to skin surface. Ann Surg Oncol (2012) 1.09

Multimodality treatment of mesenteric desmoid tumours. Eur J Cancer (2008) 1.09

MED12 mutations in leiomyosarcoma and extrauterine leiomyoma. Mod Pathol (2012) 1.09

Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother Pharmacol (2010) 1.07

Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. Mod Pathol (2012) 1.05

Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. Eur J Cancer (2009) 1.04

Cutaneous radiation-associated angiosarcoma of the breast: poor prognosis in a rare secondary malignancy. Ann Surg Oncol (2012) 1.04

Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk. Ann Surg (2014) 1.03

Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage. J Clin Oncol (2009) 1.00

Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. Ann Surg Oncol (2009) 1.00

Uterine sarcomas: then and now. AJR Am J Roentgenol (2012) 0.99

Adolescent and young adult oncology, version 2.2014. J Natl Compr Canc Netw (2014) 0.98

Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist (2011) 0.97

Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 0.95

Leiomyosarcoma. Hematol Oncol Clin North Am (2013) 0.93

Uterine neoplasms, version 1.2014. J Natl Compr Canc Netw (2014) 0.93

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib. Biologics (2010) 0.93

Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer (2007) 0.92

Secondary sarcomas after radiotherapy for breast cancer: sustained risk and poor survival. Cancer (2009) 0.92

Bone cancer. J Natl Compr Canc Netw (2010) 0.91

A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. Clin Cancer Res (2013) 0.89

Bone cancer. J Natl Compr Canc Netw (2007) 0.89

Langerhans cell histiocytosis involving the thymus. A case report and review of the literature. Arch Pathol Lab Med (2003) 0.89

External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma. Cancer (2013) 0.88

Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer (2014) 0.88

Intracranial metastasis from pediatric GI stromal tumor. J Clin Oncol (2012) 0.84

Personalized cancer therapy for gastrointestinal stromal tumor: synergizing tumor genotyping with imatinib plasma levels. Curr Opin Oncol (2010) 0.79

Uterine leiomyosarcoma: an updated series. Int J Gynecol Cancer (2013) 0.78

First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies. Clin Cancer Res (2013) 0.78

Is the nonlipomatous component of dedifferentiated liposarcoma always soft tissue on CT? Analysis of CT densities and correlation with rate of growth in 60 patients. Abdom Imaging (2015) 0.77

Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1. Am J Hypertens (2012) 0.77

Gastrointestinal stromal tumor: optimizing the use of cross-sectional chest imaging during follow-up. Radiology (2014) 0.77

Hormone dependency in metastatic low-grade leiomyosarcoma following uterine smooth muscle tumour of uncertain malignant potential. BMJ Case Rep (2014) 0.75

Synchronous small bowel and atypical primary leiomyosarcoma of inferior vena cava in a patient with RB1 mutation. Abdom Imaging (2014) 0.75

Bone cancer clinical practice guidelines. J Natl Compr Canc Netw (2005) 0.75

Clinical outcomes of women with recurrent or persistent uterine leiomyosarcoma. Int J Gynecol Cancer (2014) 0.75

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Gastrointestinal Stromal Tumors. Arch Pathol Lab Med (2015) 0.75

Solitary Fibrous Tumor of the Uterus Presenting With Lung Metastases: A Case Report. Int J Gynecol Pathol (2016) 0.75